Frontier Biotechnologies Inc
SSE:688221
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Frontier Biotechnologies Inc
Long-Term Investments
Frontier Biotechnologies Inc
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Frontier Biotechnologies Inc
SSE:688221
|
Long-Term Investments
¥30m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Long-Term Investments
¥432.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Long-Term Investments
¥7.1B
|
CAGR 3-Years
124%
|
CAGR 5-Years
253%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Long-Term Investments
¥139m
|
CAGR 3-Years
20%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Long-Term Investments
¥370.9m
|
CAGR 3-Years
233%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Frontier Biotechnologies Inc
Glance View
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
See Also
What is Frontier Biotechnologies Inc's Long-Term Investments?
Long-Term Investments
30m
CNY
Based on the financial report for Dec 31, 2024, Frontier Biotechnologies Inc's Long-Term Investments amounts to 30m CNY.
What is Frontier Biotechnologies Inc's Long-Term Investments growth rate?
Long-Term Investments CAGR 3Y
14%
The average annual Long-Term Investments growth rates for Frontier Biotechnologies Inc have been 14% over the past three years .
